Molecular Characterization of #H5N1 Clade 2.3.4.4B Virus in Vaccinated Layer #Chickens

 

Abstract

The global emergence of the avian influenza virus (AIV) H5N1 clade 2.3.4.4B since 2016 has caused substantial losses in wild bird and poultry populations, along with heightened risks of transmission to humans and other mammals. Vaccination of poultry has been a key strategy to curb the virus’s spread and mitigate its socioeconomic impact. This report describes an outbreak of high pathogenicity avian influenza virus (HPAIV) H5N1 clade 2.3.4.4B in a flock of 15,000 brown layer chickens (170 days old), all of which had received a four-dose vaccination regimen with H5N1/H5N8 commercial vaccines at 17, 50, 100, and 125 days of age. Despite this vaccination history, H5N1 infection was confirmed approximately seven weeks post-vaccination. H5N1 infection was confirmed by RT-qPCR, virus isolation, and full genome sequencing covering all eight gene segments, followed by phylogenetic and molecular analyses. Clinical signs included reduced feed intake, decreased egg production, and a cumulative mortality rate of 35% over 52 days. Hemagglutination inhibition (HI) testing with various H5 antigens revealed inconsistent antibody titers (geometric mean: 4.0 to 9.1 log2). Genetic analysis of the full-length HA and NA gene sequences further revealed strong similarity to contemporaneous H5N1 clade 2.3.4.4B strains circulating in Egypt, with multiple mutations in the HA head domain, particularly near immunogenic epitopes and receptor binding sites. These findings highlight the limitations of current vaccination strategies under conditions of antigenic mismatch and complex immunization schedules, emphasizing the need for improved vaccine matching and continuous molecular surveillance. To improve outbreak management in poultry, enhanced vaccination protocols, stringent biosecurity measures, and rigorous monitoring practices are critical.

Source: 

Link: https://www.mdpi.com/1999-4915/18/6/589

____

Epidemiological #surveillance against the #Andes virus: have we learned anything after #COVID19?

 

Summary

Recent outbreaks associated with Andes hantavirus have reignited the international debate on healthcare preparedness for hantaviruses with documented human-to-human transmission. Unlike other orthohantaviruses, Andes hantavirus has demonstrated human-to-human transmission in certain epidemiological contexts, including household and hospital settings. The recent emergence of cases linked to multinational outbreaks has prompted new assessments and recommendations from international public health organizations.

This manuscript presents an epidemiological reflection on the current challenges of surveillance against emerging hantaviruses, drawing on the experience gained during the COVID-19 pandemic. It also reviews aspects related to zoonotic surveillance, molecular monitoring, early detection, and integrated One Health approaches applied to preparedness for future emerging threats.

The available evidence suggests the need to strengthen surveillance systems capable of integrating human, environmental, and animal information to improve the response to complex epidemiological scenarios associated with emerging hantaviruses.

Source: 

Link: https://ojs.sanidad.gob.es/index.php/resp/article/view/1824

____

Updated #trends in #global #prevalence and burden of #mental #disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

 

Summary

Background

The 2023 iteration of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) estimated prevalence, incidence, and health burden for 375 diseases and injuries, including 12 mental disorders. We assess past, current, and emerging trends in the prevalence and burden of mental disorders across sexes and age groups, for 21 regions, 204 countries and territories, and by Socio-demographic Index (SDI) quintile, from 1990 to 2023.

Methods

Mental disorders included in GBD 2023 were anxiety disorders, major depressive disorder, dysthymia, bipolar disorder, schizophrenia, autism spectrum disorders, conduct disorder, attention-deficit hyperactivity disorder, anorexia nervosa, bulimia nervosa, idiopathic developmental intellectual disability, and a residual category of other mental disorders. A literature review identified epidemiological data for each disorder. These were analysed via a Bayesian meta-regression to estimate prevalence by disorder, sex, age, location, and year. Disorder-specific prevalence was multiplied by disability weights representing the severity of health loss associated with each disorder to estimate years lived with disability (YLDs). Deaths due to anorexia nervosa were assessed with a Cause of Death Ensemble modelling strategy to estimate deaths by sex, age, location, and year, and then multiplied by the standard life expectancy at age of death to estimate years of life lost (YLLs). YLDs equalled disability-adjusted life-years (DALYs) for all mental disorders except anorexia nervosa (the only mental disorder considered as an underlying cause of death in GBD), for which DALYs represented the sum of YLDs and YLLs. We presented prevalence, deaths, YLDs, YLLs, and DALYs as counts, age-specific rates per 100 000 population, and age-standardised rates per 100 000 population.

Findings

We estimated 1·17 billion (95% uncertainty interval 1·06–1·31) prevalent cases of mental disorders globally in 2023, equivalent to an age-standardised prevalence rate of 14 210·7 cases (12 849·5–15 940·1) per 100 000 population. These estimates represented a 95·5% (75·0–121·2) increase in prevalent cases and 24·2% (11·4–41·4) increase in age-standardised prevalence rate between 1990 and 2023. All mental disorders showed increases in prevalent cases between 1990 and 2023, while notable increases were seen in age-standardised prevalence rates for anxiety disorders, major depressive disorder, dysthymia, anorexia nervosa, bulimia nervosa, schizophrenia, and conduct disorder. There were an estimated 171 million (127–228) DALYs due to mental disorders globally across sex and age in 2023, equivalent to an age-standardised DALY rate of 2070·5 DALYs (1519·1–2750·5) per 100 000 population. Mental disorders contributed to 6·1% (4·8–7·6) of all-cause DALYs in 2023, making them the fifth leading cause of global DALYs (up from 12th in 1990). DALYs were almost entirely composed of YLDs. Mental disorders were the leading cause of YLDs in 2023 (up from second in 1990), explaining 17·3% (14·8–20·6) of all-cause global YLDs. Leading causes of mental disorder DALYs were anxiety disorders (ranked 11th among the 304 diseases and injuries at Level 4 of the GBD cause hierarchy), major depressive disorder (15th), and schizophrenia (41st). Globally in 2023, mental disorder age-standardised DALY rates were higher among females (2239·6 [1643·7–3014·1] per 100 000) than among males (1900·2 [1399·8–2510·8] per 100 000), and peaked in the 15–19 years age group (2617·3 [1850·6–3696·8] per 100 000). All locations showed increased mental disorder DALY rates in 2023 compared with 1990, ranging across countries and territories from 1302·4 (952·7–1683·7) per 100 000 in Viet Nam to 3555·8 (2661·9–4715·0) per 100 000 in the Netherlands. Across SDI quintiles, DALY rates ranged from 1853·0 (1352·1–2469·3) per 100 000 for middle SDI to 2184·1 (1606·1–2890·3) per 100 000 for high SDI.

Interpretation

A significant health burden was imposed by mental disorders in all countries and territories in 2023, irrespective of the health resources available. In some instances, this burden has increased over time and is unevenly distributed across populations. Stronger surveillance systems, particularly in low-income and middle-income countries, are required. Additionally, we need more coordinated and inclusive policies to reduce the burden through early treatment and prevention, tailored to sex and age differences across locations. Responding to the mental health needs of our global population, especially those most vulnerable, is an obligation, not a choice.

Funding

Gates Foundation, Queensland Health, and University of Queensland.

Source: 

Link: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00519-2/abstract?rss=yes

____

#Coronavirus #diversity and #SARS-CoV-2 #exposure at the #wildlife – #human interface in Northern #Italy

 

Abstract

Background

Members of the Coronaviridae family infect humans as well as domestic and wild animals. Over the past three decades, three members of this family, all with zoonotic origins, have caused significant epidemics or pandemics (SARS, MERS, and COVID-19). Despite the spread of SARS-CoV-2 being primarily driven by human-to-human transmission, various animal species are susceptible to infection and may contribute to viral circulation. Aim of this work was to monitor coronavirus (CoV) infections in wild mammals in the Emilia-Romagna region (RER), Italy, using a combined approach of molecular screening for viral RNA detection and serological testing for anti-SARS-CoV-2 antibodies.

Methods

Respiratory and gastrointestinal tissue samples were collected from wild animal carcasses between 2022 and 2024. Samples were tested for SARS-CoV-2 using two RT-qPCR assays targeting the E and N genes, and for other CoVs using a nested pan-coronavirus RT-PCR followed by Sanger sequencing of positive samples. Additionally, serum samples obtained from blood, cardiac clot, or thoracic exudate were screened for antibodies against the SARS-CoV-2 nucleocapsid (N) protein, with positive samples subsequently confirmed by an ELISA targeting antibodies to the receptor-binding domain (RBD) of the Spike (S) protein, focused on variants circulating during the study period.

Results

Molecular analyses were performed on 2,238 animals, all of which tested negative for SARS-CoV-2, while 90 (79% hedgehogs) tested positive for CoVs. Among these, most sequences were consistent with coronaviruses typically reported in the respective host species. However, some exceptions – such as Betacoronavirus erinacei in fox, porcupine, hare, and roe deer, and EmbeCoV-related sequences in a porcupine – warrant further attention. Suitable serum samples were available from 1,751 animals. Overall, 65 animals tested positive for anti-N antibodies, 31 of which (22 foxes, 4 badgers, 2 hedgehogs, 1 roe deer, 1 wolf, 1 rat) were subsequently confirmed by an anti-RBD ELISA.

Conclusions

This study provides an overview of CoVs circulation among wild mammals in RER, supporting the role of hedgehogs as reservoirs and identifying some species with evidence of exposure to SARS-CoV-2. Certain unexpected findings highlight the need for further investigations to clarify the potential for cross-species transmission.

Source: 

Link: https://link.springer.com/article/10.1186/s12985-026-03193-3

____

#Andes #Hantavirus #Outbreak on a Cruise #Ship, 2026 (NEJM, summary)

 

Published May 20, 2026 | DOI: 10.1056/NEJMc2606496 | Copyright © 2026

To the Editor:

    On April 27, 2026, a man (later classified as Patient 3 in the outbreak) was medically evacuated to Ascension Island from the Dutch-flagged expedition cruise ship MV Hondius; he had severe acute respiratory infection (SARI) and reported shortness of breath and fever that had begun on April 21. He had signs of pneumonia, although findings on chest radiography were unremarkable. While he was on Ascension Island, his condition worsened, and he was transferred to Johannesburg, South Africa, for ventilator support and intensive care.1 He was in shock and had acute respiratory distress syndrome; findings on chest radiography were consistent with atypical pneumonia. The differential diagnosis in this clinical context is very broad and includes atypical pneumonias, bacterial or fungal sepsis, and vectorborne diseases such as malaria or dengue. The diagnostic evaluation, including respiratory pathogen panels, malaria smear and antigen, fungal biomarkers, blood cultures, and legionella urinary antigen, was unrevealing. Further details are provided in the Supplementary Appendix, available with the full text of this letter at NEJM.org.

(...)

Source: 

Link: https://www.nejm.org/doi/full/10.1056/NEJMc2606496?query=TOC#ap1

____

A mouse #model of #human-derived #H10N3 #influenza enables preclinical evaluation of #antiviral efficacy

 

Highlights

• Revealing one human-derived H10N3 virus was highly lethal to C57BL/6J, ICR, and BALB/c mice;

• Successfully establishing the first human-derived H10N3-infected mice model.

• In vitro antiviral assay revealed that this human-origin H10N3 virus exhibits natural resistance to oseltamivir, but remains sensitive to peramivir and baloxavir.

• Oseltamivir or BM immediate treatment after infection effectively prevented mortality caused by H10N3,but their efficacy with a 24h delay were significantly weaker than that of peramivir.

• BM one-dose treatment with a 24h delay has no protective effect, but BM combination with NAIs exhibits significant additive effect on mortality caused by H10N3.

• BM and NAIs combination may be a promising therapy for combating novel H10N3 virus infection.

Abstract

    Human infections with avian influenza A (H10N3) have recently been reported, representing a notable global public health concern. To seek effective strategies for emerging H10N3 virus infection and provide tools for vaccine and antiviral drugs development, we established a mouse model with a novel human-derived H10N3 virus. Our findings revealed that this human-derived H10N3 virus was highly lethal to C57BL/6J, ICR, and BALB/c mice. Neuraminidase inhibitors (oseltamivir or peramivir) effectively conferred protection for H10N3 low-lethal infection, but the efficacy of peramivir is superior to that of oseltamivir. One single dose of baloxavir marboxil (BM) treatment at 2 h post-infection provides complete protection against mortality, but BM treatment with a 24h delay has no protective effect against mortality caused by H10N3 virus infection. Furthermore, BM multiple doses treatment with a 24h delay for H10N3 infection remains effective in preventing weight loss and enhancing viral clearance, but its protective efficacy against mortality was significantly attenuated. However, both in vitro and in vivo combination of BM with NAIs exhibit significant additive effect against H10N3 virus infection than BM or NAIs monotherapy. Our findings suggest that combination of BM with NAIs represents a promising therapeutic strategy for emerging H10N3 infections in clinical practice.

Source: 

Link: https://www.sciencedirect.com/science/article/abs/pii/S0166354226000951?via%3Dihub

____

Imported case of avian #influenza #H9N2 virus #infection in a patient with miliary #tuberculosis, #Italy, March 2026

 

Abstract

On 21 March 2026, avian influenza A(H9N2) virus was confirmed in Italy in a patient with miliary tuberculosis. The patient had recently travelled to West Africa. Following the detection of an unsubtypable influenza A virus, rapid molecular confirmation and full genome sequencing were performed. Phylogenetic analysis revealed that the virus belonged to subclade G5.5 and was closely related to African strains. Epidemiological investigations identified no additional cases, suggesting there was no evidence of onward transmission at the time of reporting.

Source: 

Link: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2026.31.15.2600285#abstract_content

____

#Coronavirus Disease Research #References (AMEDEO, May 16 '26)

 

Ann Intern Med

1. JOHNSON D, Quinn S, Algase LF, Watkins C Jr, et al
   Telemedicine Policy and Practice: A Position Paper From the American College of Physicians.
   Ann Intern Med. 2026 May 12. doi: 10.7326/ANNALS-25-04194.
   PubMed         Abstract available
   
   

   
   BMJ

2. SUMMERS C, Cook T, Suntharalingam G, Fong K, et al
   Covid Inquiry module 3 reveals critical gaps in UK health system resilience.
   BMJ. 2026;393:s846.
   PubMed        
   
   

   
   Br J Anaesth

3. FRASER S, Syratt T, Bridson JD, Gilbert-Kawai N, et al
   Refusal of blood transfusion based on donor COVID-19 vaccination status: an emerging postpandemic challenge for perioperative care.
   Br J Anaesth. 2026 May 13:S0007-0912(26)00279-5. doi: 10.1016/j.bja.2026.
   PubMed        
   
   

   
   Clin Infect Dis

4. PEREZ MA, Patel KA, Rasmy L, Yoshida H, et al
   Changes in Epidemiology of Candidemia in the United States with a Focus on Candida auris.
   Clin Infect Dis. 2026 May 11:ciag312. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

5. MENG L, Bell JM, Barbre K, Guthrie S, et al
   Using a longitudinal k-means clustering method to explore nursing home factors associated with SARS-CoV-2 infection peak and resilience to a COVID-19 surge.
   Infect Control Hosp Epidemiol. 2026 May 14:1-7. doi: 10.1017/ice.2026.10406.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

6. KIM S, Chun BC
   Heterogeneous Rebound Patterns of Foodborne Diseases after COVID-19 Non-Pharmaceutical Interventions, South Korea, 2005-2024.
   Int J Infect Dis. 2026 May 13:108782. doi: 10.1016/j.ijid.2026.108782.
   PubMed         Abstract available
   
   
7. WENG TP, Li MC, Tsai HP, Chen CJ, et al
   Viral Rebound and Clinical Outcomes in Hospitalized Patients with COVID-19.
   Int J Infect Dis. 2026 May 13:108796. doi: 10.1016/j.ijid.2026.108796.
   PubMed         Abstract available
   
   
8. SHI R, Li Y, Liu L, Wang Y, et al
   Molecular epidemiology and genomic characterization of post-pandemic macrolide-resistant Mycoplasma pneumoniae in hospitalized children.
   Int J Infect Dis. 2026 May 13:108780. doi: 10.1016/j.ijid.2026.108780.
   PubMed         Abstract available
   
   
9. MARTINEZ-DIAZ I, Nunez-Delgado S, Ortiz-Perez JT, Morales A, et al
   Increased circulating ACE2 and GAS6 are independent predictors of COVID-19 severity.
   Int J Infect Dis. 2026 May 12:108775. doi: 10.1016/j.ijid.2026.108775.
   PubMed         Abstract available
   
   
10. HEYMER EJ, Campbell H, Clark SA, Lucidarme J, et al
    Lower incidence and higher case fatality rates associated with invasive meningococcal disease during COVID-19 pandemic restrictions (March 2020 to July 2021) in England.
    Int J Infect Dis. 2026 May 10:108770. doi: 10.1016/j.ijid.2026.108770.
    PubMed         Abstract available
    
    
11. NIAMSANIT S, Sitthikarnkha P, Techasatian L, Saengnipanthkul S, et al
    Incidence Trends, Outcomes, and Factors Associated with Mortality in Multisystem Inflammatory Syndrome in Children: A Nationwide Study in Thailand during 2021-2023.
    Int J Infect Dis. 2026 May 6:108766. doi: 10.1016/j.ijid.2026.108766.
    PubMed         Abstract available
    
    

    
    J Med Virol

12. YAVUZ HC, Boysan SN, Tuna MM
    FIB-4 Index and APRI Score Predict Short- and Long-Term Mortality in Hospitalized COVID-19 Patients: A 4-Year Follow-Up Study.
    J Med Virol. 2026;98:e70964.
    PubMed         Abstract available
    
    
13. KIM DS, Kim U, Woo HM, Lee H, et al
    Broad Neutralizing Activity of Monoclonal Antibodies Against the Omicron Variants Isolated From Patients With Early Severe Acute Respiratory Syndrome Coronavirus-2.
    J Med Virol. 2026;98:e70969.
    PubMed         Abstract available
    
    

    
    J Virol

14. MCCABE M, Groves HE, Getty E, Campbell E, et al
    Age-dependent expression and antiviral activity of interferon epsilon in respiratory epithelium.
    J Virol. 2026 May 12:e0057825. doi: 10.1128/jvi.00578.
    PubMed         Abstract available
    
    
15. LI P, Zheng Y-M, Liu S-L
    Altered infectivity, cell-cell fusion, and immune evasion of SARS-CoV-2 BA.3.2 and LP.8.1 variants.
    J Virol. 2026 May 12:e0001626. doi: 10.1128/jvi.00016.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

16. HANSEN CH, Soborg B, Rasmussen M, Moustsen-Helms IR, et al
    Effectiveness of the BNT162b2 LP.8.1-adapted SARS-CoV-2 vaccine against COVID-19-associated hospitalisation and death: a Danish nationwide cohort study.
    Lancet Infect Dis. 2026 May 13:S1473-3099(26)00236.
    PubMed        
    
    

    
    N Engl J Med

17. HAYDEN FG, Shinkai M, Clark TW, Luetkemeyer AF, et al
    Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
    N Engl J Med. 2026;394:1905-1915.
    PubMed         Abstract available
    
    

    
    Nature

18. DOLGIN E
    At last, a pill that can prevent COVID after exposure to infected people.
    Nature. 2026 May 13. doi: 10.1038/d41586-026-01546.
    PubMed        
    
    

    
    Science

19. LESSLER J, Christensen A
    From wastewater analysis to public health action.
    Science. 2026;392:692.
    PubMed         Abstract available
    
    
20. HILL DT, Schulman R, Caldas IV, Dunham C, et al
    Genetic variability of SARS-CoV-2 in wastewater and associations with community transmission.
    Science. 2026;392:735-741.
    PubMed         Abstract available
    

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, May 16 '26)

 

Antiviral Res

1. PANG L, Zou J, Yuan Z, Zhao P, et al
   Repurposing screen using a robust human rhinovirus infectious clone identifies pyrvinium pamoate with antiviral activity.
   Antiviral Res. 2026;250:106417.
   PubMed         Abstract available
   
   

   
   Cell

2. QIAN W, Wei X, Barros AJ, Ye X, et al
   Respiratory viral infections prime accelerated lung cancer growth.
   Cell. 2026;189:2845-2856.
   PubMed         Abstract available
   
   

   
   Drug Saf

3. SHETTY AN, Mallard JH, Hennessy D, Wood N, et al
   Giant Cell Arteritis Following COVID-19 Vaccination: A Consumer-Stimulated Analysis.
   Drug Saf. 2026;49:705-715.
   PubMed         Abstract available
   
   

   
   J Clin Microbiol

4. SMITH ZR, Godoshian A, Boersma P, Myrick C, et al
   Evaluation of self-collection of nasal swab specimens for COVID-19 diagnostic testing in children in the United States, 2020-2023.
   J Clin Microbiol. 2026;64:e0133625.
   PubMed         Abstract available
   
   

   
   J Gen Virol

5. BHAT S, Sadeyen JR, Yang J, Chrzastek K, et al
   A G57 (BJ/94-like) H9N2 avian influenza virus exhibits enhanced replication and tissue dissemination in chickens compared with a G1-B virus.
   J Gen Virol. 2026;107.
   PubMed         Abstract available
   
   

   
   J Infect Dis

6. COLDBECK-SHACKLEY RC, Flynn E, Mudhar AK, Taouk ML, et al
   Increased Diversity and Introduction of Multidrug-Resistant Strains of Neisseria gonorrhoeae Following Cessation of COVID-19 Pandemic-Related Travel Restrictions: An Observational Genomic Epidemiologic Study.
   J Infect Dis. 2026;233:e1130-e1140.
   PubMed         Abstract available
   
   
7. LUCENA LAGE S, Rocco JM, Oguz C, Otaizo-Carrasquero F, et al
   Inflammasome Activation and Oxidative Stress in SARS-CoV-2 Infection and Symptomatic Rebound.
   J Infect Dis. 2026;233:e1285-e1297.
   PubMed         Abstract available
   
   
8. BOECKH M, Xie H, Stevens-Ayers T, Sircy L, et al
   Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes.
   J Infect Dis. 2025 Dec 31:jiaf649. doi: 10.1093.
   PubMed         Abstract available
   
   
9. ZHANG R, Shang X, Wang C, Zhou H, et al
   Rhinovirus-Associated Lower Respiratory Tract Infection in Hospitalized Adult Patients: A Retrospective Cohort Study.
   J Infect Dis. 2026;233:868-876.
   PubMed         Abstract available
   
   

   
   J Virol

10. XU C, Peng Y, Liu S, Xie R, et al
    Cellular hnRNP D promotes influenza A virus replication by inhibiting TBK1-IRF3-mediated innate immune response.
    J Virol. 2026 May 13:e0025726. doi: 10.1128/jvi.00257.
    PubMed         Abstract available
    
    
11. CHEN X, Zheng X, Zhang L, Cai X, et al
    Long noncoding RNA#61 synergizes with viral PA-X to augment pyroptosis and attenuate the virulence of highly pathogenic H5N1 influenza virus in mice.
    J Virol. 2026 May 12:e0221425. doi: 10.1128/jvi.02214.
    PubMed         Abstract available
    
    
12. VAN PUL L, Rosendahl Huber SK, Jacobi R, Hendriks M, et al
    Cross-reactive antibody and T-cell responses after influenza virus infection in community-dwelling older adults.
    J Virol. 2026 May 12:e0040726. doi: 10.1128/jvi.00407.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

13. ROLFES MA, Bauck L, Lipton BA, Margrey SF, et al
    Knowledge, Attitudes, and Practices Regarding Avian Influenza Among Owners of Backyard Flocks - United States, July-December 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:234-239.
    PubMed         Abstract available
    
    
14. ROLFES MA, Bauck L, Lipton BA, Margrey SF, et al
    Knowledge, Attitudes, and Practices Regarding Avian Influenza Among Owners of Backyard Flocks - United States, July-December 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:234-239.
    PubMed         Abstract available
    
    

    
    N Engl J Med

15. HAYDEN FG, Shinkai M, Clark TW, Luetkemeyer AF, et al
    Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
    N Engl J Med. 2026;394:1905-1915.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

16. KIERAN TJ, Maines TR, Belser JA
    Limited 'heft' of weight-based outcomes in predicting influenza A virus disease severity in ferrets.
    PLoS Comput Biol. 2026;22:e1014210.
    PubMed         Abstract available
    
    
17. YU G, Garee M, Ventresca M, Yih Y, et al
    Modeling individual self-protective behavior during epidemics.
    PLoS Comput Biol. 2026;22:e1014252.
    PubMed         Abstract available
    
    

    
    PLoS Med

18. GOODFELLOW L, Quilty BJ, van Zandvoort K, Edmunds WJ, et al
    Social contact patterns in the United Kingdom following the COVID-19 pandemic: The Reconnect cross-sectional survey.
    PLoS Med. 2026;23:e1005038.
    PubMed         Abstract available
    
    

    
    PLoS One

19. ZOUGHEIB Y, Salameh N, Slim A, Wehbi Z, et al
    Effect of screen time and outdoor activities on myopia progression.
    PLoS One. 2026;21:e0347118.
    PubMed         Abstract available
    
    
20. YEHIA N, Ibrahim M, Shady RM, Mohamed AAE, et al
    Concurrent circulation of avian influenza viruses H5N1 and H9N2 enhances the genetic evolution of reassortant viruses in Egyptian poultry populations.
    PLoS One. 2026;21:e0348609.
    PubMed         Abstract available
    
    
21. CANTON L, Schalkwijk P, Landier J, Rebaudet S, et al
    Socioeconomic inequalities and the COVID-19 pandemic in France: Territorial analyzes based on epidemic wave and metropolitan area.
    PLoS One. 2026;21:e0348201.
    PubMed         Abstract available
    
    
22. SUGIYAMA A, Takafuta T, Abe K, Yoshinaga Y, et al
    Differences in the long-term course of post-COVID-19 symptoms in adults and children across epidemic periods: A retrospective cohort study in Japan, 2020-2024.
    PLoS One. 2026;21:e0348954.
    PubMed         Abstract available
    
    
23. HUGHES A, Barnard S, Bauer-Staeb C, Holleyman R, et al
    Life lost due to the COVID-19 pandemic: A model-based cohort analysis of mortality displacement in the registered population of England.
    PLoS One. 2026;21:e0348575.
    PubMed         Abstract available
    
    
24. LIU Y, Lu E, Ellingson KD, Hollister J, et al
    Unveiling post-vaccination proteomic signatures in SARS-CoV-2 infection-naive individuals associated with Omicron breakthrough infections.
    PLoS One. 2026;21:e0347602.
    PubMed         Abstract available
    
    
25. FREITAS EL, Erbisti RS, Grinberg-Weller B, Pinto DCC, et al
    Spatiotemporal analysis of psychoactive drug consumption in Brazil during the COVID-19 pandemic.
    PLoS One. 2026;21:e0343552.
    PubMed         Abstract available
    
    
26. TOGEL J, Kuhbandner C
    Fear and the internalization of external regulation - An exploratory study on how fear of COVID-19 affected the internalization of mask-wearing.
    PLoS One. 2026;21:e0347772.
    PubMed         Abstract available
    
    
27. MILLER SL, Yan S, Garcia A, Wang LL, et al
    Potential airborne transmission of SARS-COV-2 through bathroom ventilation ducts associated with an outbreak in a residential building in Santander, Spain, 2020.
    PLoS One. 2026;21:e0345041.
    PubMed         Abstract available
    
    
28. DOMINGUEZ-MONTERROZA A, Jimenez-Martin A, Mateos Caballero A
    Network geometry, topology, and spectral analysis in global stock markets: Insights from using the Ricci curvature, Euler characteristic, and random matrix theory.
    PLoS One. 2026;21:e0347767.
    PubMed         Abstract available
    
    
29. BRAUN J, Kopp J, Kunzi L, Puhan MA, et al
    Measurement properties of the 30-second sit-to-stand test in post COVID-19 condition: Results from the PYCNOVID randomised controlled trial.
    PLoS One. 2026;21:e0348275.
    PubMed         Abstract available
    
    
30. LAURENCE J, Smyth E
    COVID-19 pandemic stressors and their longer-term association with young people's wellbeing.
    PLoS One. 2026;21:e0347875.
    PubMed         Abstract available
    
    
31. SCHERBOV S, Pothisiri W, Prasitsiriphon O, Ediev DM, et al
    Survival and life expectancy inequality by gender in Thai provinces: Trends from 2015 to 2023.
    PLoS One. 2026;21:e0348587.
    PubMed         Abstract available
    
    
32. AZANERO-HARO J, Soto A
    Comparison of the performance of four clinical prediction rules for mortality in patients with COVID-19.
    PLoS One. 2026;21:e0348683.
    PubMed         Abstract available
    
    
33. PENG Y
    Sustainability-induced loyalty in festival tourism: Examining the mediating pathways between sustainable practices and visitor behavioral support.
    PLoS One. 2026;21:e0348506.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

34. KEARNS FL, Bogetti AT, Calvo-Tusell C, Braza MKE, et al
    D614G reshapes allosteric networks and opening mechanisms of SARS-CoV-2 spikes.
    Proc Natl Acad Sci U S A. 2026;123:e2504793123.
    PubMed         Abstract available
    
    
35. SIMKO T, Johnson RA
    Alleviating administrative burdens in rental assistance promotes access and program efficiency.
    Proc Natl Acad Sci U S A. 2026;123:e2512756123.
    PubMed         Abstract available
    
    

    
    Vaccine

36. CARLOCK MA, Ross TM
    Retooling a novel influenza B hemagglutinin to redirect neutralizing antibodies against B/Victoria strains.
    Vaccine. 2026;84:128674.
    PubMed         Abstract available
    
    

    
    Virology

37. WANG R, Chen J, Zhang H, Qin Y, et al
    Characterization of monoclonal antibody and identification of two novel linear epitopes on the hemagglutinin protein of H3N2 canine influenza virus.
    Virology. 2026;621:110923.
    PubMed         Abstract available
    
    
38. DING K, Ding Y
    H5N1 avian influenza in dairy cattle: Molecular adaptation, transmission mechanisms, and control strategies.
    Virology. 2026;621:110927.
    PubMed         Abstract available
    
    
39. ZHANG Y, Liu L, Chen T, Li M, et al
    CD25(+) cell depletion enhances protective immunity of PR8 inactivated influenza vaccine in aged mice.
    Virology. 2026;621:110938.
    PubMed         Abstract available

Membrane-anchored #influenza #neuraminidase vaccine drives #human-like broadly protective B cell responses

 

Abstract

Influenza neuraminidase (NA) is a promising target for universal flu vaccines, yet eliciting potent B-cell responses against its conserved epitopes remains challenging. Here, we developed a membrane-anchored, folding-domain-free NA (mNA) that elicited superior head-specific germinal center B cell and antibody responses compared to soluble tetrameric NA. In non-human primates, mNA immunization induced cross-reactive memory B cell (MBC) responses, expanding clones with the conserved DR motif in HCDR3, a hallmark of human broadly reactive NA antibodies. These MBCs conferred cross-inhibitory activity against diverse NA variants and in vivo cross-protection. Cryo-EM analysis revealed that the 554-C2 clone targets the conserved enzymatic pocket via the DR motif, while the 554-C1 clone recognizes previously uncharacterized epitopes at the interface between two adjacent N2 monomers, effectively reducing plaque formation by contemporary H3N2 strains. Our findings highlight the immunological advantages of membrane-anchoring, providing a robust strategy for designing next-generation vaccines against influenza and other pathogens.

Competing Interest Statement

Westlake University has filed for patent protection for mNA used as an influenza vaccine.

Funder Information Declared

State Key Laboratory of Gene Expression, SKLGE-ZX-2025007

Zhejiang Provincial Key Laboratory Construction Project, 2024ZY01026, 2024E10060, 2024E10052

Natural Science Foundation of Zhejiang province, LR26H190001

National Natural Science Foundation of China, 82471855, 825B2062, 82330054, 82502209, 32471303

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.05.13.724804v1

____

A Panel of #Human Monoclonal #Antibodies for Tracking the #Antigenic #Evolution of #Influenza #H5N1 Clade 2.3.4.4b

 

Abstract

The ongoing panzootic of clade 2.3.4.4b H5N1 influenza has resulted in widespread infection of birds, mammals, and livestock, underscoring the need for tools to interpret its real-time evolution. Here, we describe the isolation and characterization of a panel of 19 human monoclonal antibodies that potently neutralize current isolates. Competition immunoassays and cryo-electron microscopy analyses revealed their collective near-complete epitope coverage of the H5-hemagglutinin surface. Neutralization profiling across multiple historical and contemporary H5 viruses defined their epitope-specific patterns of virus neutralization. One cluster of antibodies potently neutralized only clade 2.3.4.4b viruses, while many others exhibited broadly neutralizing activity against diverse H5N1 clades. Application of this structurally calibrated antibody panel to recent North American human isolates revealed genotype-specific antigenic divergence between lineages that have spread among cattle (B3.13) and poultry (D1.1). Together, the findings of this study establish a structurally grounded antibody reference panel spanning major vulnerable sites of H5 hemagglutinin and provide a toolbox for interpreting emergent mutations, monitoring ongoing antigenic drift, and anticipating the evolutionary trajectory of circulating H5N1 influenza viruses.

Competing Interest Statement

H.H., M.W., S.C., J.Y., Y.H., Y.G., and D.D.H. are inventors on the provisional patent application filed by Regeneron for several H5N1 neutralizing antibodies described herein. D.D.H. is a co-founder of TaiMed Biologics and RenBio, consultant to Brii Biosciences, and board director for Vicarious Surgical.

Funder Information Declared

Gates Foundation, INV019355

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.05.14.725215v1

____

#Reassortant High Pathogenicity Avian #Influenza #H5N1 Viruses During the Reemergence in #Uruguay Suggest Increasing #Genetic Diversity in South #America

 

Abstract

Highly pathogenic avian influenza (HPAI) H5N1 viruses of the goose/Guangdong (Gs/GD) lineage have driven a global panzootic since 2020, with clade 2.3.4.4b establishing sustained transmission in wild birds. In South America, early outbreaks were largely associated with the North American-derived B3.2 genotype, which showed limited diversification after its introduction. Here, we report the genomic characterization of eight H5N1 viruses detected in Uruguay during the reemergence of avian influenza in February–March 2026. Complete genomes were obtained from wild birds exhibiting neurological signs, predominantly Coscoroba coscoroba. All viruses belong to clade 2.3.4.4b but exhibit a reassortant genomic constellation distinct from B3.2. The HA, NA, and MP segments retain the Eurasian backbone, whereas internal genes derive from both South American and North American low-pathogenicity avian influenza lineages. PB2 variation distinguishes two closely related viral groups differing in PB2 origin, whereas the remaining genomic segments retain a shared background. Sequence variation in the neuraminidase gene reduced the sensitivity of a widely used N1-specific RT-qPCR assay, highlighting limitations of existing diagnostic tools during viral evolution. These findings confirm the presence of reassortant H5N1 viruses in Uruguay and, together with recent reports from Argentina and Brazil, support an emerging pattern of genomic diversification in southern South America.

Source: 

Link: https://www.mdpi.com/1999-4915/18/5/558

____

#Diagnostic and #clinical #challenges of #hantavirus-associated acute #kidney injury

 

Abstract

Introduction: 

Hantavirus infection is an uncommon zoonosis in Europe but remains an important cause of acute kidney injury, particularly in patients with environmental exposure to rodents. Renal involvement is the hallmark of the disease, although pulmonary manifestations may coexist and mimic immune-mediated pulmonary–renal syndromes, leading to diagnostic challenges in internal medicine.

Case description: 

A 46-year-old previously healthy man living in a rural area was admitted for acute febrile illness with asthenia and myalgia. Initial investigations revealed severe thrombocytopenia and acute kidney injury with proteinuria and microscopic haematuria. A computed tomography scan of the chest and abdomen showed bilateral pulmonary abnormalities, consistent with an acute pulmonary–renal syndrome. Extensive immunological and infectious investigations excluded autoimmune disease and alternative infectious causes. Hantavirus infection was confirmed by positive IgM and IgG serology, with molecular identification of Puumala virus. Renal biopsy demonstrated moderate acute tubular necrosis with minimal interstitial inflammation and preserved glomeruli. The patient was treated with supportive care only, resulting in rapid clinical improvement and complete recovery of renal function.

Conclusion: 

Hantavirus infection should be considered in patients presenting with acute pulmonary–renal syndrome, thrombocytopenia, and compatible epidemiological exposure. Early diagnosis allows appropriate supportive management, avoids unnecessary immunosuppressive therapy, and is associated with an excellent renal prognosis in Puumala virus infection.

Source: 

Link: https://www.ejcrim.com/index.php/EJCRIM/article/view/6159

____

Concurrent #Detection of #Swine-Origin #Influenza #H1N1 Virus in #Pigs and #Farmer, #Switzerland

 

Abstract

We report zoonotic transmission of Eurasian avian-like swine influenza A(H1N1) virus from pigs to a farmer. The pigs and farmer experienced influenza-like illness. Whole-genome sequencing revealed >99.9% isolate sequence identity between hosts. Our findings highlight the risk posed by enzootic swine influenza A virus and the need for genomic and epidemiologic surveillance.

Source: 

Link: https://wwwnc.cdc.gov/eid/article/32/6/25-1487_article

____

#Ensitrelvir for #Covid19 Postexposure #Prophylaxis in #Household Contacts

 

Abstract

Background

Ensitrelvir, an oral inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease, is approved in Japan for the treatment of mild-to-moderate coronavirus disease 2019 (Covid-19). Previously, no antiviral agents were approved for postexposure prophylaxis in household contacts of patients with Covid-19.

Methods

In this double-blind, randomized, placebo-controlled trial, we randomly assigned persons who were SARS-CoV-2–negative on local diagnostic testing but were household contacts of a patient with Covid-19 (the index patient) to receive either ensitrelvir (375 mg on day 1 and 125 mg daily on days 2 through 5) or placebo within 72 hours after symptom onset in the index patient. The primary end point was Covid-19 (defined by a central laboratory–confirmed positive reverse-transcriptase–polymerase-chain-reaction assay and the presence of ≥1 of 14 prespecified Covid-19 symptoms lasting ≥48 hours) by day 10 in a household contact in the modified intention-to-treat population (all the participants who underwent randomization, had a central laboratory–confirmed negative RT-PCR test for SARS-CoV-2 at baseline, and received at least one dose of the trial drug or placebo).

Results

The modified intention-to-treat population included 1030 participants in the ensitrelvir group and 1011 in the placebo group. The mean age of the participants was 42.4 years; 71.1% had undergone randomization within 48 hours after symptom onset in the index patient, and 37.0% had at least one risk factor for severe Covid-19. The incidence of Covid-19 was lower in the ensitrelvir group than in the placebo group (2.9% vs. 9.0%; risk ratio, 0.33; 95% confidence interval [CI], 0.22 to 0.49; P<0.001). The incidence of adverse events during the trial was similar in the two groups (15.1% in the ensitrelvir group and 15.5% in the placebo group), as was the incidence of serious adverse events (0.2% in each group). No Covid-19–related hospitalizations or deaths were reported.

Conclusions

Ensitrelvir administered to household contacts of a patient with Covid-19 within 72 hours after symptom onset in the index patient was effective in preventing Covid-19 in the contacts. (Funded by Shionogi; SCORPIO-PEP Japan Registry for Clinical Trials number, jRCT2031230124; ClinicalTrials.gov number, NCT05897541.)

Source: 

Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2509306?query=TOC

____

#Outbreak of #H9N2 avian #influenza viruses in lesser #rhea in #Peru, June-July 2025

 

Abstract

Avian influenza viruses (AIVs) are endemic in the Americas and responsible for outbreaks in both domestic and wild birds that occasionally spill over into humans. We report the first known outbreak of AIV H9N2 in lesser rhea (Rhea pennata), also known as Darwin’s rhea, in the region of Puno-Peru. The animals in this study lived in an isolated conservation center located in remote highlands above 4,000 m.a.s.l. Between June and July 2025, a total of 46/92 animals were recorded sick, with symptoms including greenish diarrhea (100%), hyporexia (24%), dyspnea (76%), nasal discharge (42%), drowsiness (18%) and isolation from the flock (73%), and 94% later died. Gross pathology exams revealed septicemia characterized by severe hepatitis, pneumonia, tracheitis, enteritis, and encephalitis. Swab and necropsy samples tested positive for Influenza A by PCR and were later identified as H9N2 through whole genome sequencing. We generated complete H9N2 genomes for two individuals. No additional pathogens were found. Phylogenetic analysis across all eight segments revealed that the viruses were low pathogenicity H9N2 AIV strains of North American origin, which indicated this outbreak was a new introduction of the virus into South America. We also performed a comparative mutational analysis and identified multiple mutations previously associated with mammalian host adaptation, increased virulence, increased pathogenicity, and increased virus binding to α2-6 receptors, which may explain the high mortality rates observed despite the supposedly low pathogenicity of the strain. We also identified novel mutations specific to rhea viruses that will need to be experimentally validated. This is the first report of a natural H9N2 systemic infection in an avian host, highlighting a need for increased surveillance efforts for zoonotic influenza viruses with pandemic potential.

Competing Interest Statement

The authors have declared no competing interest.

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.05.08.723762v1

____

Emerging and re-emerging vector-borne and other #zoonotic #RNA #viruses: #pathogenesis, #climate-driven dynamics, and strategies for global control

 

Abstract

Vector-borne and other zoonotic RNA viruses provide a significant and growing threat to global health, especially in areas where climate change, urbanization, and population growth facilitate the proliferation of arthropod vectors. This review offers an extensive examination of the biology, epidemiology, and pathogenesis of numerous important viruses, including dengue, Zika, chikungunya, yellow fever, Japanese encephalitis, Crimean–Congo hemorrhagic fever, Nipah, Ebola, and hantaviruses. We underscore how environmental and social factors, particularly increasing temperatures, modified precipitation patterns, and accelerated urbanization, transform vector habitats and spillover dynamics. The article further analyzes host–virus and virus–vector interactions, highlighting mechanisms of immune evasion, neurotropism, and vascular disease. Computational and machine learning models are examined as novel instruments for forecasting outbreaks and developing early warning systems. Finally, a summary of present and prospective control options is provided, covering integrated vector management, Wolbachia-based biological control, vaccinations, and antiviral immunotherapies.

Source: 

Link: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2026.1755594/full

____

Pre-existing systemic and #nasal #antibodies against avian #H5 #influenza A viruses vary according to #childhood imprinting

 

Abstract

Avian influenza A viruses (IAV) pose a constant pandemic threat, with the recent 2.3.4.4b clade of the H5 subtype causing high pathogenicity and spreading across animal species and geographic locations. Understanding human pre-existing immunity to avian H5 IAV can inform on population susceptibility, a critical aspect of pandemic preparedness. To that end, we analysed the IAV HA-specific antibodies across individuals born between 1928-1999 with different early life exposures to IAV subtypes. Individuals born prior to 1957 had the highest pre-existing serum antibodies to group 1 HA antigens, including the 2.3.4.4b H5 and a group 1 HA stem antigen. These birth-year-specific patterns were not reflected in the limited pre-existing serum neutralising antibodies detectable against a 2.3.4.4b H5 IAV or in H5-specific memory B cell populations. They were however evident in pre-existing nasal IgG and IgA titres to H5, which were greater in individuals born prior to 1957. Our findings demonstrate that the immunological biases afforded by early life exposure extend to antibodies detected in the nasal mucosa, the site of IAV replication.

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.05.08.723737v1

____

G4 #Eurasian avian-like #H1N1 swine #influenza viruses exhibit enhanced #pathogenicity potential in mice and #pigs

 

Abstract

Currently circulating swine influenza viruses (SIVs) mainly include H1N1, H1N2, and H3N2 subtypes. In this study, two G4 genotype Eurasian avian-like (EA) H1N1 SIVs were isolated from 556 samples collected between 2023 and 2026. A systematic analysis was conducted on the two EA H1N1 isolates (FYD30 and YZF69) to assess their pandemic potential. The hemagglutinin (HA) proteins of both H1N1 viruses possessed residues 225E and 228S, indicating enhanced affinity for human-like alpha-2,6-linked sialic acid receptors, which was confirmed by receptor-binding assays. Polymerase activity tests demonstrated that the two SIVs exhibited significantly higher activity in mammalian cells, relative to avian cells, which is consistent with the efficient replication in mammalian cells. Challenge experiments revealed that both H1N1 caused significant pathogenicity in mice and pigs, with YZF69 exhibited higher virulence than FYD30. The higher virulence of YZF69 may be attributed to its molecular features, including the NP Q357K mutation, and an additional glycosylation site in HA. In conclusion, currently circulating EA H1N1 SIVs have acquired key molecular signatures of mammalian adaptation, exhibit enhanced virulence in mammals, and continue to undergo extensive reassortment driven by international swine trade. These findings highlight the potential pandemic risk of SIVs and underscore the urgent need for strengthened surveillance.

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.05.12.724537v1

____

The #Coinfection of #Bartonella spp. and #Hantavirus in Wild #Rodent and #Shrew Species in Eastern #China

 

Abstract

Background:

Bartonella spp. are Gram-negative bacteria that cause diseases including endocarditis, lymphadenopathy, and neuroretinitis. Hantavirus (HV), belonging to the family Hantaviridae, induces illnesses such as hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Both pathogens exhibit host specificity—defined as a preference or restriction to specific host species or ranges. Rodents and shrews are primary hosts for these pathogens, and their high coinfection rates often indicate elevated risk of human exposure. To our knowledge, however, data on Bartonella spp.–HV coinfection in rodents and shrews from Eastern China remain limited.

Materials and Methods:

Between 2020 and 2023, rodents (n = 311) and shrews (n = 16) were investigated for coinfection with Bartonella spp. and HV in Qingdao, eastern China. Nested Polymerase Chain Reaction (PCR) was used for the detection of RNA-dependent RNA polymerase (RdRp) gene of HV and the Internal Transcribed Spacer, citrate synthase (gltA) and RNA polymerase beta subunit (rpoB) genes of Bartonella spp.

Results:

The overall infection rates of Bartonella spp., HV, and coinfection were 21.4%, 6.7%, and 4.0%, respectively. The highest rates were observed in Apodemus agrarius (53.8%, 21.3%, and 15.0%). Coinfection rates differed significantly by species (p < 0.05), with A. agrarius exhibiting the highest rate (15.0%). Notably, the coinfection rate was significantly higher in male (28.9%) than female A. agrarius (7.1%) (p < 0.05).

Conclusions:

This study confirms the coinfection of Bartonella spp. and HV in rodents in the eastern region of China. Enhanced monitoring of rodent and shrew densities, as well as their carried pathogens, is essential. Additionally, timely screening, diagnosis, and treatment should be conducted for high-risk populations in the region to reduce the incidence of related zoonoses.

Source: 

Link: https://journals.sagepub.com/doi/10.1177/15303667261448824

____